Emergent BioSolutions (EBS) Other Non-Current Liabilities (2010 - 2026)

Emergent BioSolutions' Other Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $41.7 million for Q1 2026.

• In Q1 2026, Other Non-Current Liabilities rose 17.8% year-over-year to $41.7 million; the TTM figure through Mar 2026 stood at $41.7 million (up 17.8% YoY), while the FY2025 annual figure was $53.9 million, up 37.85% from the prior year.
• Other Non-Current Liabilities was $41.7 million for Q1 2026 at Emergent BioSolutions, down from $53.9 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $58.5 million in Q2 2022 to a low of $4.4 million in Q1 2022.
• Historically, Other Non-Current Liabilities has averaged $35.7 million across 5 years, with a median of $35.8 million in 2024.
• Biggest YoY gain for Other Non-Current Liabilities was 1070.0% in 2022; the steepest drop was 88.42% in 2022.
• A 5-year view of Other Non-Current Liabilities shows it stood at $41.5 million in 2022, then plunged by 30.36% to $28.9 million in 2023, then jumped by 35.29% to $39.1 million in 2024, then surged by 37.85% to $53.9 million in 2025, then slipped by 22.63% to $41.7 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $41.7 million (Q1 2026), $53.9 million (Q4 2025), and $42.6 million (Q3 2025), per Business Quant data.